Royal Bank of Canada (RY)
165.99
+2.55 (1.56%)
NYSE · Last Trade: Mar 10th, 3:28 PM EDT
Detailed Quote
| Previous Close | 163.44 |
|---|---|
| Open | 164.31 |
| Bid | 165.94 |
| Ask | 166.00 |
| Day's Range | 163.76 - 167.17 |
| 52 Week Range | 106.10 - 176.19 |
| Volume | 565,859 |
| Market Cap | 237.47B |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | 4.528 (2.73%) |
| 1 Month Average Volume | 1,373,899 |
Chart
About Royal Bank of Canada (RY)
Royal Bank of Canada is a leading financial services institution that provides a wide range of banking and financial solutions to individuals, businesses, and institutions. The bank offers personal and commercial banking services, wealth management, investment banking, and capital markets services. With a robust network of branch locations and digital platforms, it aims to meet the diverse needs of its clients while focusing on innovation and customer service. Royal Bank of Canada is committed to enhancing the financial well-being of its customers and leveraging its expertise to support economic growth in the communities it serves. Read More
News & Press Releases

Atmus Filtration Technologies supplies filtration products for commercial vehicles and industrial equipment to OEMs and aftermarket clients.
Via The Motley Fool · March 10, 2026
Citi CEO Jane Fraser details Q1 investment banking, markets progress, sheds light on industry trends at RBC conference.
Via Investor's Business Daily · March 10, 2026

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B. Riley slashed YEXT target, Stifel cut MTN target, RBC raised KNTK target, Truist cut MAA target, Wells Fargo raised XENE target, Citigroup raised HIMS target.
Via Benzinga · March 10, 2026
On March 9, 2026, RBC Capital Markets issued a significant upgrade for Dow Inc. (NYSE: DOW), elevating the chemical giant from "Sector Perform" to "Outperform" and raising its price target from $29.00 to $40.00. This bullish pivot comes as a direct response to escalating geopolitical instability in the
Via MarketMinute · March 9, 2026
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.
Via Stocktwits · March 9, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · March 8, 2026
A cautious but opportunistic approach using three TSX stocks can help navigate the current war-driven volatility and ensuing market sell-offs.
Via The Motley Fool · March 8, 2026
Verizon has unexpectedly emerged as a hot stock in 2026.
Via The Motley Fool · March 7, 2026
A high-yield TSX stock can provide sustained monthly income streams and temper investors’ war-driven anxiety.
Via The Motley Fool · March 6, 2026
A top-performing crypto stock could crash hard and be worthless if volatility spikes under the current market conditions.
Via The Motley Fool · March 6, 2026

Boyd Group Services operates a broad network of collision repair and auto glass centers serving insurance providers across North America.
Via The Motley Fool · March 6, 2026
What Happened? Shares of aviation and defense services provider AAR CORP (NYSE:AIR) fell 7.3% in the afternoon session after reports revealed concerns that r...
Via StockStory · March 5, 2026
Two analysts have big concerns about these stocks.
Via The Motley Fool · March 5, 2026
As the closing bell approaches on March 4, 2026, all eyes on Wall Street are fixed on Broadcom Inc. (NASDAQ:AVGO), which is set to report its first-quarter fiscal 2026 results. The semiconductor giant finds itself at a critical crossroads, balancing a massive $73 billion AI-driven backlog against mounting investor
Via MarketMinute · March 4, 2026
It's not only the market sell-off that has investors clicking the sell button today.
Via The Motley Fool · March 3, 2026
SCOTTSDALE, AZ — Shares of Axon Enterprise, Inc. (NASDAQ: AXON) surged a remarkable 26% this week, marking a historic technical breakout for the public safety technology leader. The rally followed a massive fourth-quarter 2025 earnings beat that silenced skeptics and solidified the company’s transition from a hardware manufacturer into a
Via MarketMinute · March 3, 2026
Wall Street remains split on whether AI will accelerate Salesforce’s growth or pressure traditional SaaS models, with Agentforce seen as a key test.
Via Stocktwits · March 3, 2026
The next few quarters should be very prosperous for the company, but one pundit following has some concerns about the longer-term future.
Via The Motley Fool · March 2, 2026
Shares of edge cloud platform Fastly (NYSE:FSLY) jumped 7.4% in the afternoon session after RBC Capital raised its price target on the stock to $20 from $12 as investor meetings with management provided reassurance about the company's improving execution.
Via StockStory · March 2, 2026
On March 2, 2026, the global financial landscape witnessed a stark divergence as the energy sector emerged as the sole survivor in an otherwise bruising day for equity markets. While the S&P 500 and the Nasdaq Composite tumbled under the weight of "AI fatigue" and renewed inflationary fears, the
Via MarketMinute · March 2, 2026
RBC Capital analyst Srini Pajjuri lowered the price target on Broadcom to $340 from $370 and maintained a ‘Sector Perform’ rating on its shares.
Via Stocktwits · March 2, 2026
Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.
Via Stocktwits · March 2, 2026

Wall Street analysts changed outlook on top names: BTIG cut CRWD PT, Piper Sandler cut BSY PT, RBC Capital cut AARD PT, TD Cowen raised TWLO PT, Morgan Stanley raised FLYW PT, Stifel boosted QSR PT, Morgan Stanley increased ZION PT, HC Wainwright cut IMUX PT
Via Benzinga · March 2, 2026
Abishai Financial Asia Pte. Ltd. is tracking Apotex Inc.’s move towards a Toronto public offering in the current quarter, a deal targeting up to $730 million in proceeds and putting a sizeable Canadian generic-drug platform back in front of equity investors. The latest full-year disclosure points to about $2.1 billion of revenue, with the core generic franchise expanding 12% over the prior financial year.
Via AB Newswire · March 2, 2026
The Iran conflict could fuel a return of triple-digit crude prices.
Via The Motley Fool · March 2, 2026
